Amid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites. This decisive action follows extensive inspections -- over 960 since late last year -- triggered by tragic child fatalities linked to these drugs. By December 31, manufacturers must adhere to World Health Organization standards.